Lloyd M. Segal

Biotechnology and healthcare leader, advisor and investor.

[Harley Finkelstein @harleyf]

Happy Canada Day 🇨🇦

My family came to Canada after the Hungarian Revolution in 1956.

My grandfather stood behind a broken table in torn clothing selling eggs hoping this country would give his family a chance.

I am proof that it did.

Canada gave my family safety. It gave us opportunity. It gave me the chance to become an entrepreneur and help build one of Canada’s most important companies.

That’s why I spend so much time talking about what Canada needs to fix. Not because I’ve lost faith in this country, but because I believe so deeply in what it can be.

I never want to lose sight of what Canada has given my family.

Lindsay and I chose to raise our daughters here because we still believe in this country.

That’s worth fighting for.

[Lloyd M. Segal @LM_Segal]

Excited to have Steven’s Stein’s wisdom and experience added to our Board today!

[Repare Therapeutics @RepareRx]

Please join @RepareRx in welcoming Dr. Steven H. Stein to our Board of Directors, effective June 17, 2024. Dr. Stein currently serves as the Chief Medical Officer of Incyte Corporation, a position he has held since March 2015.

[Lloyd M. Segal @LM_Segal]

Thrilled to have @FoundationATCG as a partner in helping us genomically match the patients who will most benefit from our new medicines! #precisiononcology #syntheticlethality

[Repare Therapeutics @RepareRx]

We are collaborating with @FoundationATCG to deliver genomic profiling to patients in our lunresertib clinical trials and beyond. We are thrilled to take this next step with potential to develop a companion diagnostic and expand access to clinical trial sites for lunresertib.

[Harley Finkelstein @harleyf]

Today, @cafreeland is introducing a motion to increase the capital gains inclusion rate in Canada. This isn't a wealth tax — it's a tax on innovation and risk-taking.

Investing in new products or ideas is inherently risky. Entrepreneurs need incentives, not penalties, to drive 🇨🇦 ​forward.

This policy will disincentivize risk-taking and tax Canadian ambition at a time when we need more entrepreneurs, not fewer.

The OECD predicts Canada will be the worst-performing advanced economy for per-person GDP growth until 2060. Killing our tax competitiveness is not the way to fix this.

We need to change course, and fast.

[Harley Finkelstein @harleyf]

We need to be doing everything we can to turn Canada into the best place for entrepreneurs to build 🇨🇦

What's proposed in the federal budget will do the complete opposite. Innovators and entrepreneurs will suffer and their success will be penalized -- this is not a wealth tax, it's a tax on innovation and risk taking.

Our policy failures are America's gains. At a time when our country is facing critically low productivity and business investment our political leaders are failing our country's entrepreneurs.

Please start listening to the people in the arena.

[Repare Therapeutics @RepareRx]

First patient has been dosed with camonsertib in @Roche's Phase II global TAPISTRY trial treating patients with unresectable, locally advanced or metastatic #solidtumors. We are grateful to patients and investigators who are part of our shared mission. https://t.co/RJ2opy4fQZ

[Lloyd M. Segal @LM_Segal]

Exciting new data today in @RepareRx lunre+camo combo, showing remarkable early efficacy signals and 50% RECIST response in 10 gyn patients at prelim RP2D and 60% OR in that initial group. Phenomenal new opportunity for patients & amazing work by the team and investigators!

[Repare Therapeutics @RepareRx]

At #Targets23, we presented positive initial data from Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib. Join our live webcast today at 5:30pm ET, where we will be discussing the results. Read more: https://t.co/m3iYGDMfm8

[Lawrence H. Summers @LHSummers]

In nearly 50 years of @Harvard affiliation, I have never been as disillusioned and alienated as I am today.

[Repare Therapeutics @RepareRx]

Be sure to join @RepareRx live video webcast - which will feature additional updates from this week’s abstracts and highlight the significant potential we see for this combination - on Friday 10/13 at 5:30 p.m. ET: https://t.co/gtb6tIfpRX

[Repare Therapeutics @RepareRx]

We look forward to presenting positive, new clinical data from our lunresertib + camonsertib MYTHIC combination trial, which includes a more mature data cut (Sept vs June in abstract) of more patients treated at clinically relevant doses next Friday at #Targets23.

[Roberto Bellini @rbellini]

The uninformed perception is that biotech success can be easy. Find a great drug, run a trial with a great result, get bought out! Join me on a thread that explores the Bellus journey and how hard the path to drug development success can really be. $BLU $XBI

[Lloyd M. Segal @LM_Segal]

Apologies for the Friday pm call 😥 but AACR-NCI-EORTC selected our data for a plenary presentation during the day Friday.

[Repare Therapeutics @RepareRx]

Repare will host a conference call & webcast to discuss initial Phase 1 MYTHIC clinical data presented at the @AACR @theNCI @EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15. Additional details: https://t.co/SlJ2PLAaJl

[Lloyd M. Segal @LM_Segal]

Looking forward to sharing important new @RepareRx data across multiple programs and achievements by the team, including a plenary talk by Dr Timothy Yap on the Lunre-Camo combination!

[Repare Therapeutics @RepareRx]

At the upcoming @AACR @theNCI @EORTC International Conference, Repare will present data from its ongoing Phase 1 MYTHIC clinical trial in a plenary session, in addition to multiple posters presentations. Learn more: https://t.co/2F5szRtcDL #Targets23

[Lloyd M. Segal @LM_Segal]

Incredibly proud of this recognition of our work, the courage of the patients participating in our trials and the leadership, perseverance, dedication and innovation of the awesome, global team at @Repare and of our collaborators. #precisiononcology #syntheticlethality

[Repare Therapeutics @RepareRx]

Thank you to @BIOTECanada for naming Repare as the 2023 Gold Leaf Award for Top Established Biotech Company of the Year! We’re thrilled to be chosen and honored to join an impressive group of previous winners in the category.

[Repare Therapeutics @RepareRx]

Repare’s management team is participating in a fireside chat at the @MorganStanley Annual Global Healthcare Conference in NYC next week. We look forward to connecting in person! Click here to watch the webcast: https://t.co/DgEOL3oLbv

[Lloyd M. Segal @LM_Segal]

A watershed Q for us as @Roche activates clinical starts of camonsertib globally + our multiple portfolio advances, with lunresertib data coming up + 2 new clinical programs. More great progress from amazing @RepareRx team + collaborators. #precisioncology #syntheticlethality

[Repare Therapeutics @RepareRx]

Today, we announced our second quarter 2023 financial results and provided a business update. Full press release with additional details: https://t.co/O4VWGexfV3

#precisiononcology #syntheticlethality $RPTX

[Repare Therapeutics @RepareRx]

Today, we announced our first quarter 2023 financial results and provided a business update. Full press release with additional details: https://t.co/DVffHGUsc8
#precisiononcology #syntheticlethality $RPTX

[Lloyd M. Segal @LM_Segal]

Sorry - Daniel Lamarre! Wish Twitter had edits …

[Lloyd M. Segal @LM_Segal]

Really enjoyed this morning’s panel at #LESI2023, #cirquedesoleil Daniel Bellemare a tough act to follow!

[IRICoR @IRICoR_]

#LESI2023 Today @ElizDouville has the chance to talk to @LM_Segal,@CharlieGore,@GCMcCauley,Yasunori Yamaguchi about their unique approaches to commercializing IP
The degree of control that an entity retains depends upon the different forms of technology transfer
Let's discuss it!

[Repare Therapeutics @RepareRx]

Senior Scientist, David Gallo, will be speaking at @Gyne_Oncology’s 23rd Continuing Professional Development meeting to discuss the use of CRISPR-based screening to identify new targets within #gynecologiccancer. Register here: https://t.co/TSad4L7MBi